Background: Thirdhand smoke (THS) represents the accumulation of secondhand smoke on indoor surfaces and in dust, which, over time, can become more toxic than secondhand smoke. Although it is well known that children of smokers are at increased risk for asthma or asthma exacerbation if the disease is already present, how exposure to THS can influence the development or exacerbation of asthma remains unknown. Objective: We investigated whether epicutaneous exposure to an important component of THS, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), can influence asthma pathology in a mouse model elicited by means of repeated intranasal challenge with cockroach antigen (CRA). Methods: Wild-type mice, a7 nicotinic acetylcholine receptor (nAChR)-or mast cell (MC)-deficient mice, and mice with MCs that lacked a7 nAChRs or were the host's sole source of a7 nAChRs were subjected to epicutaneous NNK exposure, intranasal CRA challenge, or both, and the severity of features of asthma pathology, including airway hyperreactivity, airway inflammation, and airway remodeling, was assessed. Results: We found that a7 nAChRs were required to observe adverse effects of epicutaneous NNK exposure on multiple features of CRA-induced asthma pathology. Moreover, MC expression of a7 nAChRs contributed significantly to the ability of epicutaneous NNK exposure to exacerbate airway hyperreactivity to methacholine, airway inflammation, and airway remodeling in this model. Conclusion: Our results show that skin exposure to NNK, a component of THS, can exacerbate multiple features of a CRAinduced model of asthma in mice and define MCs as key
Exposure to environmental tobacco smoke is a significant health concern, and recent attention has focused on possible roles of thirdhand smoke (THS) in patients with tobacco-related diseases. THS is the residual tobacco smoke contamination remaining after the source of tobacco smoke has been extinguished. 1 Tobacco smoke contaminants, including nicotine, persist in places where people smoke (eg, homes and cars) and can potentially cause adverse health effects. [2] [3] [4] [5] Nicotine adsorbed onto indoor surfaces can react with ozone and gaseous nitrous acid (a pollutant in vehicle exhaust that also is produced by improperly vented gas stoves and burning tobacco) to yield potentially bioactive residues, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 1-(N-methyl-N-nitrosamino)-1-(3-pyridinyl)-4-butanal (NNA), and N9-nitrosonornicotine, the 3 main tobacco-specific nitrosamines formed in the reaction of gaseous nitrous acid and sorbed nicotine. 6 In the United States approximately 43% of children aged 2 months to 11 years live with a smoker. 2 Infants and young children are thought to be at greater risk for THS exposure than adults because they typically spend more time indoors, and crawling babies can absorb chemicals through the skin. 7, 8 Moreover, THS exposure can cause alterations in multiple organ systems. 9 For example, exposure to THS can result in increased collagen production and levels of inflammatory cytokines in the lung. 9 THS exposure can also increase the risk of thrombosis 10 and insulin resistance 11 and impair wound healing. 12 It is thought that the biological effects of major THS components (nicotine and its metabolites: NNK, NNA, and N9-nitrosonornicotine) are mediated by nicotinic acetylcholine receptors (nAChRs), including the high-affinity receptor for NNK, a7 nAChR. 13 In addition to neurons, many other cell types express a7 nAChR, including immune cells, such as B 14, 15 and T 16, 17 lymphocytes, regulatory T cells, 18 dendritic cells, 19, 20 macrophages, 21 eosinophils, 22 and mast cells (MCs). [23] [24] [25] [26] However, little is known about the mechanisms that link THS exposure to disease.
Asthma is characterized by inflammation of the airways, airway hyperreactivity (AHR), airflow obstruction, and airway wall remodeling. 27, 28 MCs are cells of hematopoietic origin 29, 30 that complete their maturation and then reside in virtually all tissues. [29] [30] [31] Repetitive activation of airway MCs by antigen-specific IgE and its cognate antigen is thought to play a key role in asthma pathology in many subjects, 32 and activation of MCs by IgE and specific antigen is regarded as the main process by which MCs contribute to atopic asthma and other allergic disorders. [33] [34] [35] [36] [37] [38] Although mouse, 24, 39, 40 rat, 25, 41 and human 23, 42 MCs express a7 nAChRs, there have been few studies of the effects of a7 nAChR agonists on MCs, and all such data (except for a study of mucosal MCs in a model of food allergy 39 and ours, as discussed below) are from in vitro work. Such findings indicate that MC responses to a7 nAChR signaling (eg, degranulation or cytokine production) can vary, depending on the concentration or type of a7 nAChR agonist, the type of MCs studied, and the presence or absence of concomitant IgE/FcεRI signaling. [24] [25] [26] 39 Although the possible role of MCs in asthma exacerbation by THS components has not been studied, measurement of markers of asthma severity, such as exhaled nitric oxide, indicate that exposure to even low levels of THS can cause significant airway inflammation. 43 In the present study we exposed mice repeatedly to intranasal cockroach antigen (CRA), the most important allergen for eliciting asthma in inner-city households in the United States, [44] [45] [46] to establish a mouse model of CRA-induced asthma. We then used this mouse model to define the extent to which epidermal exposure to NNK could influence the severity of asthma pathology and investigate to what extent MCs contributed to any observed effects of NNK.
METHODS Mice
All animal experiments were carried out according to protocols approved by the Stanford University Administrative Panel on Laboratory Animal Care. Genetically MC-deficient C57BL/6 (B6)-Kit W-sh/W-sh mice were generously provided by Peter Besmer (Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY); these mice were then backcrossed to C57BL/6J (B6J) mice for more than 10 generations. 47 
RESULTS
Both NNK and the a7 nAChR agonist PNU282987 can exacerbate allergic airway inflammation elicited after intranasal CRA challenge
In wild-type (WT) C57BL/6J (B6J) mice, our CRA-induced model (intranasal CRA challenge with 10 mg of CRA/0.03 mL of PBS on days 1, 2, 15, 18, and 21) resulted in significantly increased airway reactivity (ie, AHR) to methacholine (measured as lung resistance [R L ]) and increased numbers of total leukocytes in bronchoalveolar lavage fluid (BALF), as well as significant increases (vs mice challenged with PBS instead of CRA) in BALF neutrophils, eosinophils, and lymphocytes (Fig 1) . We found that intraperitoneal application of either the a7 nAChR agonist PNU282987 (10 mg/kg body weight [BW] in 0.2 mL of normal saline 5 minutes before performing intranasal challenge with CRA on days 1, 2, 15, 18, and 21), epicutaneous painting of the left ear pinna (indicated with a red circle in Fig E1, A, in this article's Online Repository at www.jacionline.org) with NNK (0.5 mg/kg BW in 0.01 mL of ethanol 5 minutes before the CRA challenge on days 1, 2, 15, 18, and 21), or intraperitoneal PNU282987 injection plus epicutaneous NNK painting significantly exacerbated CRA-induced AHR (Fig 1, A) and increased numbers of BALF total leukocytes and neutrophils (Fig 1, B) versus corresponding values in mice that received neither PNU282987 nor NNK. Intraperitoneal injection of PNU282987 plus epicutaneous NNK painting also increased numbers of BALF eosinophils and lymphocytes (Fig 1, B) . These findings indicate that exposure to NNK, the a7 nAChR agonist PNU282987, or both can exacerbate features of allergic airway inflammation, including AHR to methacholine and numbers of BALF leukocytes, in this CRA-induced mouse model of asthma.
In this model intranasal CRA challenge elicited a combination of T H 1 and T H 2 cell immune responses, as assessed in both systemic immunity and the inflamed site (the lung, see Fig E2 in this article's Online Repository at www.jacionline.org), which could be further promoted by epicutaneous exposure to NNK (see Fig E2) . Dexamethasone treatment significantly decreased intranasal CRA-induced AHR (see Fig E2, A) accompanied by a decrease in the magnitude of inflammation (eg, leukocyte infiltration and cytokine expression; see Fig E2, B-E). Epicutaneous NNK exposure could counter the effect of dexamethasone treatment on reducing plasma levels of IFN-g and IL-33. Nevertheless, expression of IFN-g and IL-9 in both the lung and spleen, as elicited by means of intranasal CRA or intranasal CRA plus epicutaneous NNK exposure, was always resistant to dexamethasone treatment (see Fig E2, C-E).
Host expression of a7 nAChRs is required for epicutaneous NNK exposure to exacerbate CRA-induced asthma pathology Based on the finding that either NNK or the a7 nAChR agonist PNU282987 could exacerbate CRA-induced airway pathology, we assessed the extent to which the ability of epicutaneous exposure to NNK to exacerbate asthma pathology required expression of a7 nAChRs. We found that the features of CRA-induced asthma pathology that were elicited in a7 nAChR-deficient B6J-Chrna7 2/2 mice were very similar to those observed in the identically treated WT mice, including AHR to methacholine; increased numbers of total bronchoalveolar lavage (BAL) leukocytes and BAL neutrophils, eosinophils, and lymphocytes; and interstitial infiltration of neutrophils and eosinophils in the lung (Figs 2 and 3) , as well as increased numbers of goblet cells in the airway epithelium (ie, goblet cell hyperplasia) and increased lung collagen content (and subepithelial collagen deposition, Fig 3) . However, epicutaneous exposure to NNK, which significantly exacerbated all of these features of asthma pathology in CRA-challenged WT mice, was essentially without effect in CRA-challenged B6J-Chrna7 2/2 mice (Figs 2 and 3 ). These findings indicate that host expression of a7 nAChRs is required for epicutaneous application of NNK to exacerbate AHR, airway inflammation, and airway remodeling in our CRA-induced asthma model.
MCs contribute to multiple features of this CRA-induced asthma model
In B6-Cpa3-Cre; Mcl-1 fl/fl (HK) or B6J-Kit W-sh/W-sh mice, both of which are markedly deficient in MCs, intranasal CRA challenge did not elicit AHR to methacholine but did induce slightly but significantly increased numbers of total BALF leukocytes and BALF neutrophils, eosinophils, and lymphocytes versus PBStreated control valuess; however, the magnitude of such increases in MC-deficient mice was significantly lower than that in corresponding CRA-treated B6-Cpa3-Cre; Mcl-1 1/1 or B6J mice (Fig 4, A N 5 5 to 6 mice per group. ＊ P < .05, ＊ ＊ P < .01, or ＊ ＊ ＊ P < .001 versus corresponding PBS-treated controls (Fig 1, A) or the group indicated (Fig 1, A and B) . In Fig 1 , B, P < .05, .01, or .001 between the PBS-treated control group (not presented in the figures) versus the corresponding groups treated with CRA, PNU plus CRA, or NNK plus CRA. To simplify data presentation (in Fig 1, A) , the PBS group depicted includes 3 randomly selected mice from each of the intranasal PBS control groups (in the presence or absence of treatment with NNK, PNU, or both) in these experiments. There were no statistically significant differences in responses observed in each of these PBS-treated control groups.
(BMCMCs or ''MCs''; B6J-Charma7 1/1 MCs/HK or B6J-Charma7 1/1 MCs/Kit W-sh/W-sh mice) exhibited AHR to methacholine and features of allergic airway inflammation and airway wall remodeling that were statistically indistinguishable from those observed in the corresponding WT mice (Figs 4-6 and see Fig E3) . Therefore, based on analyses in 2 types of MC-deficient mice whose MC deficiency reflects different genetic mechanisms, the development of these phenotypic features of asthma in this mouse model appeared to be largely MC dependent.
MC expression of both the FcεRI g chain and a7
nAChRs is required for epicutaneous NNK exposure to exacerbate CRA-induced asthma pathology MCs can be activated to release cytokines and other inflammatory mediators in response to the engagement of bivalent or multivalent antigen by antigen-specific IgE bound to IgE receptors (FcεRIs) on the MC surface. Moreover, it has been reported that such IgE-dependent MC mediator production can be reduced by exposure of MCs to NNK during the activation process. [24] [25] [26] To assess the potential in vivo relevance of this finding, we investigated whether NNK could enhance features of asthma pathology in B6-Fcer1g 2/2 MCs/B6J-Kit W-sh/W-sh mice (MC-deficient Kit W-sh/W-sh mice that had been selectively engrafted with BMCMCs from FcεRI g chain-deficient Fcer1g 2/2 mice), in which MCs lack the signaling g chain of the FcεRI. In such mice MCs cannot be activated by FcεRI-dependent mechanisms (eg, by specific antigen and antigen-specific IgE). We found that B6-Fcer1g
MCs/B6J-Kit W-sh/W-sh mice subjected to our CRA-induced model of asthma exhibited little or no AHR to methacholine and had significantly lower numbers of BALF leukocytes after CRA challenge than did the corresponding WT (Fcer1g (Fig 3, A) and Masson trichrome-stained (Fig 3, B) tissue sections of lungs demonstrating peribronchial or perivascular inflammatory infiltrates and mucus-secreting goblet cells (blue, some indicated with arrows) and subepithelial fibrosis (blue-stained collagen) 24 hours after the last intranasal CRA challenge. C and D, Numbers of neutrophils and eosinophils in lungs. E, Numbers of goblet cells along the airway epithelium. F, Lung collagen levels. N 5 5 to 6 mice per group. ＊P < .05, ＊ ＊P < .01, or ＊ ＊ ＊P < .001 versus corresponding PBS-treated controls or the group indicated. Scale bars 5 50 mm (Fig 3, A) or 30 mm (Fig 3, B) . Fig E4, C) . These findings indicate that expression of the FcεRI g chain by the engrafted MCs was required for full development of the increase in lung MC numbers observed in the CRA-induced asthma model. This observation is consistent with similar findings reported by us in a chronic model of asthma induced by the antigen ovalbumin (OVA). 49, 50 Notably, epicutaneous exposure of CRA-challenged Fcer1g
2/2
MCs/Kit W-sh/W-sh mice to NNK neither enhanced airway responses to methacholine nor increased numbers of total (or individual types of) BALF leukocytes versus values in mice treated with CRA alone, whereas such effects of NNK exposure were observed in the Fcer1g 1/1 MCs/Kit W-sh/W-sh mice subjected to CRA challenge (see Fig E4) . NNK exposure also had little or no effect on numbers of lung MCs in either CRA-challenged Fcer1g MCs/HK mice were significantly increased by means of epicutaneous exposure to NNK (Figs 4, C and D; 5; and 6). By contrast, although the features of CRA-induced asthma pathology in Chrna7 2/2 MCs/HK mice were similar to those in the corresponding Chrna7 1/1 MCs/HK mice, these features were not exacerbated further in mice also exposed epicutaneously to NNK exposure (Figs 4, C and D; 5; and 6).
These findings show that this NNK exposure protocol cannot significantly exacerbate the features of our CRA-induced asthma model in MC-engrafted HK mice in which the engrafted MCs are selectively deficient in a7 nAChRs. In addition, our findings also show that MC expression of a7 nAChRs was necessary for exposure to NNK to promote increased production of antigen-specific IgE/IgG 1 , as well as increases in plasma levels of IFN-g, IL-5, IL-9, and IL-33 (see Fig E5 in this article' s Online Repository at www.jacionline.org).
Evidence that expression of a7 nAChRs exclusively in MCs is sufficient for epicutaneous NNK exposure to induce exacerbation of the CRA-induced asthma pathology Our experiments in mice globally deficient in a7 nAChRs indicated that a7 nAChRs are required for epicutaneous exposure to NNK to exacerbate the features of the CRA-induced asthma model (Figs 2 and 3) , and we provided evidence that a7 nAChR expression by MCs is required also (Fig 4, C and D; Figs 5 and 6 ). However, many cells in addition to MCs can express a7 nAChRs, [23] [24] [25] [26] 41, 42 and we wondered whether non-MCs that bear a7 nAChRs can be needed also for epicutaneous exposure to NNK to exacerbate features of the CRA-induced asthma model. We addressed this question by performing experiments in mice in which MCs were the only cell that expressed a7 nAChRs. Specifically, we generated B6J-Chrna7 MCs/B6J-Chrna7
mice, which remained globally deficient in a7 nAChRs but had both MCs and an intact antigen/IgE/FcεRI signaling pathway).
We found that intranasal CRA induced features of allergic airway inflammation and airway remodeling in both B6J-
MCs/B6J-Chrna7 mice) subjected to intranasal antigen CRA challenge or to epicutaneous exposure to NNK and intranasal CRA challenge (NNK 1 CRA). Scale bars 5 50 mm (Fig 5, A-H ) or 20 mm (Fig 5, I -P).
MCs/B6J-Kit W-sh/W-sh mice or B6J-Chrna7 1/1 MCs/B6J-Chrna7 2/2 -Kit W-sh/W-sh mice) treated with NNK plus CRA did not exhibit significant differences in the numbers of MCs engrafted in the lungs (Fig 8, C) . In aggregate, these findings suggest that NNK-dependent exacerbation of asthma pathology in this CRA model is largely dependent on MC expression of a7 nAChRs but that other a7 nAChR-bearing cells also can contribute to at least some of the findings.
Taken together, our observations indicate that the effects of NNK on a7 nAChRs expressed by FcεRIg-expressing MCs contribute significantly to the ability of epicutaneous exposure to NNK to exacerbate the severity of multiple features of the asthma pathology elicited in mice by the clinically relevant antigen CRA.
DISCUSSION
In this study we established a mouse model of asthma based on repeated intranasal challenges with the clinically relevant antigen CRA. This CRA-induced model exhibits several major features of asthma, including AHR to methacholine, airway inflammation, and airway wall remodeling. Using this model, we identified an unexpected mechanism by which epicutaneous exposure to NNK, a major component of THS, can exacerbate several features of asthma pathology. Specifically, we found that epicutaneous exposure to NNK (for which the a7 nAChR is the high-affinity receptor 13 ) can enhance AHR to methacholine, airway inflammation, and airway wall remodeling in the CRA-induced model and that for NNK to do this requires that MCs express both a7 nAChRs and functionally active FcεRIs. We also found that epicutaneous exposure to NNK can exacerbate certain features of asthma pathology in a different mouse model, that induced by OVA in the absence of artificial adjuvant (see Fig E6 in this article' s Online Repository at www.jacionline.org).
Our results are unexpected in part because a number of studies have suggested that nicotine or other agonists of nAChRs can activate an a7 nAChR-dependent anti-inflammatory mechanism (reviewed by de Jonge and Ulloa 51 ), findings that contributed to a growing body of evidence showing that the central nervous system can modulate components of the immune system. 52 Indeed, the so-called ''cholinergic anti-inflammatory pathway'' and its potential to influence immune responses and inflammatory cascades have attracted substantial interest because of their obvious relevance to a variety of debilitating human diseases. 51, 53, 54 However, there is conflicting evidence about the importance of this pathway in vivo. In some studies nicotine or nicotinic agonist were found to reduce lung inflammation, AHR, and levels of antigen-specific IgE in mouse models significantly, 55, 56 observations supporting an anti-inflammatory role for nicotine and cholinergic pathways. By contrast, Mishra et al 41 reported that although systemic administration of nicotine strongly diminished lung T H 2 responses in antigen-challenged rats, which had been sensitized with ragweed or house dust mite antigen plus aluminum hydroxide, nicotine treatment neither reduced b-hexosaminidase levels in the BALF nor diminished methacholine-induced airway resistance in vivo but significantly increased airway intraepithelially stored mucus and expression of Muc5ac mRNA. The latter study indicates that nicotine treatment can decrease, increase, or have no significant effects on various features of rodent models of asthma.
In our CRA-induced mouse model of asthma, we detected no evidence for the NNK-dependent activation of a cholinergic anti-inflammatory pathway that can mitigate the inflammatory response. To the contrary, we found that in this CRA-induced model of asthma, intraperitoneal administration of the a7 nAChR agonist PNU282987 or epidermal application of NNK promoted the development of AHR and airway inflammation (Fig 1) . Subsequent experiments were consistent with this finding and provided evidence for the important role of MCs and MC expression of a7 nAChRs in contributing to the ability of exposure to NNK to exacerbate asthma pathology in this model. Notably, BMCMCs/Chrna7 2/2 -Kit W-sh/W-sh mice). B, Numbers of total or individual types of leukocytes in BALF from mice 24 hours after the last intranasal CRA or PBS administration. ＊P < .05, ＊ ＊P < .01, or ＊ ＊ ＊P < .001 versus corresponding PBS-treated controls or the group indicated. N 5 5 to 6 mice per group. To simplify data presentation, the PBS group depicted in the graphs includes 3 randomly selected mice from the PBS control group of each strain of mice used in these experiments. There were no statistically significant differences in the responses observed in each of these PBS-treated control groups. ) mice. ＊P < .05, ＊ ＊P < .01, or ＊ ＊ ＊P < .001 versus the corresponding PBS-treated controls or the group indicated. N 5 5 to 6 mice per group. To simplify data presentation, the PBS group depicted in the graphs includes 3 randomly selected mice from the PBS control group for each strain of mouse that had been engrafted with the same strain of BMCMCs used in these experiments. There were no statistically significant differences in the responses observed in each of these PBS-treated control groups.
our mouse model of asthma is based on use of an allergen that is clinically relevant in that CRA has been reported to be the most important allergen for eliciting asthma in inner-city households in the United States. [44] [45] [46] Although we performed these experiments mainly using B6-HK mice (which are genetically deficient in MCs through a mechanism that does not depend on abnormalities in c-Kit or its expression), we found that similar results were obtained in experiments using either HK mice or B6J-Kit W-sh/W-sh genetically MC-deficient mice as recipients of transfer of WT or genetically altered BMCMCs (Fig 4 and see Fig E3) . This encouraged us to use B6J-Kit W-sh/W-sh mice to generate mice that both essentially lack MCs and are globally deficient in a7 nAChRs. These mice permitted us to show that expression of a7 nAChRs solely in adoptively transferred MCs is sufficient for epicutaneous exposure to NNK to enhance multiple features of our CRA-induced asthma model in MC-engrafted B6J-Chrna7 2/2 -Kit W-sh/W-sh mice. It is well known that the children of smokers are at increased risk for asthma and for asthma exacerbations of asthma if the disease is already present. [57] [58] [59] [60] Moreover, it has been proposed that cigarette smoking and exposure to secondhand smoke can contribute to worse outcomes and diminished effectiveness of steroid therapy in asthmatic patients. [61] [62] [63] Other evidence supports the idea that short-and long-term effects of tobacco smoke exposure can influence the structure of the developing lung, as well as lung physiology, effects that can have lifelong consequences, [64] [65] [66] [67] and there is evidence that the most common preventable early-life risk factor for asthma is exposure to tobacco smoke. 68 Long-term exposure of mice to THS can induce pulmonary toxicity by itself. 9 However, our study indicates that in mice exposure to a component of THS, even at doses too low to induce obvious histologic effects on the lungs, can significantly exacerbate multiple features of asthma pathology. The extent to which our findings are relevant to human subjects exposed to both environmental allergens and THS remains to be determined, and in vivo studies like those we performed in mice could not be considered in human subjects because of obvious ethical concerns. However, our findings in this mouse model of asthma show that the effects on MCs of one component of THS can exacerbate pathologic features of asthma and raise the possibility that such a pathway can contribute to some of the adverse health effects of environmental exposure to nicotine, nicotine-derived nitrosamines, or both.
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Key messages
d Skin exposure to the THS component NNK can exacerbate features of asthma pathology in a mouse model.
d MC expression of a7 nAChRs contributes to the ability of skin exposure to NNK to exacerbate asthma pathology in this model. 
METHODS

MC engraftment
Airway challenge with CRA
Mice were subjected to intranasal administration of 10 mg of CRA (a mixture of whole-body extract of American cockroach [Periplaneta americana]; Greer Laboratories, Lenoir, NC) in 0.03 mL of PBS on days 1, 2, 15, 18, and 21; control mock-sensitized mice received intranasal challenges with PBS on the same schedule.
Epicutaneous exposure to NNK
Mice were subjected to epidermal painting on the inner side of the left ear pinna with NNK (Sigma-Aldrich, St Louis, Mo) at 0.5 mg/kg BW in 0.01 mL of ethanol on days 1, 2, 15, 18, and 21 in each instance 5 minutes before CRA challenge. Dermal painting of NNK (0.5 mg/kg BW in 0.01 mL of ethanol) did not induce ear swelling and vasodilation, which was confirmed by using the Evans blue test and measurement of ear thickness (Fig E1, A and B) . Cellculture experiments also revealed that NNK alone could not induce MC degranulation (Fig E1, C) .
It has been reported that exposure of mice to THS (which has been shown to contain NNK E3 ) under conditions that mimicked exposure of human subjects can induce a proinflammatory environment in the lung, including infiltration of inflammatory cells and increased lung collagen (by using Masson trichrome stain). Therefore we performed preliminary experiments to define an amount of NNK that did not by itself induce histologically detectable lung inflammation. We found that 5 epicutaneous applications of NNK, consisting of 0.5 mg/ kg BW NNK per treatment, did not elicit a histologically detectable inflammatory response, such as infiltration of inflammatory cells into the lung, nor did it increase levels of lung collagen, as assessed in Masson trichrome-stained sections (Fig E1, D) .
is the principal metabolite of NNK. Urinary concentrations of NNAL can be measured to quantitatively estimate exposure to NNK. E4 In the present study the urinary NNAL level measured 24 hours after the last epicutaneous NNK exposure was 1259 6 221 pg/mL (614-2461, pg/mL). This measurement was performed at the Clinical Pharmacology Laboratory, University of California, San Francisco. The potential endotoxin contamination of NNK was excluded by means of examination with a Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific, Waltham, Mass). In addition, we confirmed the influence of epicutaneous NNK exposure on airway recruitment of neutrophils by excluding the influence of endotoxin. Specifically, we subjected TLR4-deficient Tlr4 2/2 mice to intranasal CRA challenge versus intranasal CRA challenge plus epicutaneous NNK exposure (Fig E7) . This further demonstrated the significant similarity of the pattern of responses of Tlr4 2/2 versus WT Tlr4 1/1 mice either to intranasal CRA challenge or intranasal CRA challenge plus epicutaneous NNK exposure in the expression of the cytokines IFNg, IL-5, and IL-9 in the lungs and spleens (Fig E7, B and C) .
Measurement of airway reactivity to methacholine
Invasive measurements of airway reactivity in anesthetized, tracheostomized, mechanically ventilated mice were performed 24 hours after the last intranasal exposure (eg, to CRA or PBS) by using the Mouse RC system (BUXCO Research Systems, Wilmington, NC). Aerosolized methacholine was administered in increasing concentrations (0, 10, 20, and 40 mg/mL), with individual doses separated by 2 minutes. R L was continuously computed by fitting flow, volume, and pressure to an equation of motion for each aerosol challenge period, which consisted of a 0.5-minute aerosol exposure and a 1.5-minute period after exposure, as described previously.
E1,E2
BAL and histology
For BAL, mice were killed by using CO 2 inhalation 24 hours after the last CRA or PBS challenge. The left lung was ligated and removed for protein extraction, whereas the right lung lobes were lavaged once with ice-cold HBSS (BAL) and then fixed (10% formaldehyde) and paraffin embedded. Paraffin sections of 5 mm were mounted on Superfrost Plus glass slides (Fisher Scientific) and stained with hematoxylin and eosin or Masson trichrome stain.
On hematoxylin and eosin-stained tissue sections, neutrophils and eosinophils were identified according to their morphologic features. At least 8 typical peribronchial regions (cross-sections from the basement membrane to the alveolar wall) per mouse were randomly selected in a blinded fashion for neutrophil/eosinophil counting in 6 high-power fields (3400 total magnification), which were located at the positions of 12, 2, 4, 6, 8, and 10 o'clock. MCs were identified in toluidine blue-stained tissue sections. At least 8 typical peribronchial regions were randomly selected, and numbers of MCs were counted in a blinded fashion throughout the entire peribronchial regions. The areas examined for neutrophils/eosinophils or for MC counting were measured by using the Image Pro Plus imaging software system (Media Cybernetics, Rockville, Md). Goblet cells were identified by using Masson trichrome staining. At least 8 typical bronchial cross-sections were randomly selected, and numbers of goblet cells along the bronchial epithelium were counted in a blind fashion. The length of the bronchial epithelium was measured with the Image Pro Plus imaging software system (Media Cybernetics).
Tissue protein extraction
Lung or spleen tissue protein was extracted by using the T-PER Tissue Protein Extraction Reagent purchased from Thermo Scientific (Rockford, Ill). Half of the left lung or one third of the spleen was placed into 1 mL of protein extraction reagent, followed by homogenization, and then the samples were centrifuged at 10,000g for 5 minutes to pellet cell/tissue debris; supernatants were collected for further analyses.
Protein, collagen, and cytokine measurements
Protein levels of tissue samples were measured by using a BCA Protein Assay Kit purchased form Thermo Scientific. Tissue collagen levels were measured with a Sircol Soluble Collagen Assay Kit purchased from Biocolor (Carrickfergus, United Kingdom). ELISA kits for measuring IFN-g, IL-5, IL-9, and IL-33 were purchased from Thermo Fisher Scientific.
Airway challenge with OVA Female C57BL/6 mice at 10 weeks of age were sensitized by means of 3 intraperitoneal injections of 50 mg of OVA (Sigma-Aldrich) per injection in 0.1 mL of PBS on days 1, 4, and 7. Starting on day 12, these mice were subjected to intranasal challenge with 20 mg of OVA/0.03 mL of PBS weekly 9 times (Fig E6, A) ; control mice received intraperitoneal injections and intranasal challenges with PBS on an identical schedule.
E1,E2
Statistics
Differences in airway reactivity between the different groups were tested for statistical significance by using repeated ANOVA followed by the Fisher's protected least significant difference (PLSD) test (StatView, version 5.0.1). Unless otherwise specified, differences among experimental groups in the same strain of mice were assessed by using ANOVA, followed by Tukey-Kramer tests, whereas differences between groups of mice of different strains that were subjected to identical treatment were tested with the unpaired Student t test (2-tailed; GraphPad InStat, version 3.0.1; GraphPad Software, La Jolla, Calif). A P value of less than .05 was considered statistically significant. Unless otherwise specified, all data are presented as means 6 SEMSs. Each experiment reported here has been repeated twice to confirm their reproducibility, which generated similar results. FIG E1. A, WT C57BL/6 (B6) mice were injected intravenously with 0.2 mL of Evans Blue dye (50 mg/kg BW in normal saline) and then painted epicutaneously (e.c.) with NNK (0.5 mg/kg BW/0.01 mL of ethanol) or ethanol (0.01 mL) on left ear skin (red circle). Thirty minutes later, there was no NNK-induced increase in Evans Blue extravasation. B, Ear thickness of NNK-exposed mice measured at the site indicated with a red circle in Fig E1, A, with a dial thickness gauge (G-1 A, Ozaki, Japan) was not altered significantly compared with vehicle-painted control values. C, Culture supernatants of anti-DNP IgE-sensitized BMCMCs from C57BL/6 mice collected (for calculation of % histamine release) 1 hour after addition of DNP-HSA, NNK, or both. ＊ ＊P < .01 or ＊ ＊ ＊P < .001 versus each group generated without DNP-HSA stimulation (0 ng/mL) or versus the indicated group (data are from 3 independent experiments). D, Masson trichrome-stained lung sections in C57BL/6 mice subjected to epicutaneous (e.c.) NNK (0.5 mg/kg BW/0.01 mL of ethanol at days 1, 2, 15, 18 and 21 five minutes before intranasal [i.n.] PBS administration; right) versus those in mice subjected to epicutaneous exposure to ethanol and intranasal PBS administration alone (left; tissues collected 24 hours after the last intranasal PBS administration). Scale bars 5 100 mm (upper panels) or 30 mm (lower panels). H&E, Hematoxylin and eosin. W-sh/W-sh mice). B, Numbers of individual types of leukocytes in BALF recovered from mice 24 hours after the last intranasal administration of CRA or PBS. ＊P < .05, ＊ ＊P < .01, or ＊ ＊ ＊P < .001 versus the corresponding PBS-treated controls or the group indicated; P < .05, P < .01, or P < .001 versus the corresponding group of Kit W-sh/W-sh mice. N 5 5 to 6 mice per group. To simplify data presentation, the PBS group depicted in the graphs includes 3 randomly selected mice from the PBS control group of each strain of mouse used in these experiments. There were no statistically significant differences in the responses observed in each of these PBS-treated control groups. A, Protocol: female C57BL/6 mice were sensitized with 3 intraperitoneal (i.p.) injections of 50 mg of OVA in 0.1 mL of PBS each, followed by 9 weekly intranasal (i.n.) challenges with OVA (20 mg per challenge). Some mice were subjected to epicutaneous NNK exposure on days 54, 61, and 69 five minutes before intranasal OVA challenge with 0.5 mg of NNK/kg BW in 0.01 mL of ethanol. B, AHR to methacholine (assessed as R L ) 24 hours after the last intranasal challenge with CRA or PBS. C, Numbers of individual types of leukocytes in BALF recovered from mice 24 hours after the last intranasal challenge with OVA or PBS. ＊P < .05, ＊ ＊P < .01, or ＊ ＊ ＊P < .001 versus PBS-treated controls or the group indicated. N 5 5 mice per group. To simplify data presentation, the PBS group depicted in the graphs includes 3 randomly selected mice from each of the intranasal PBS control groups, including PBS-treated mice with epicutaneous NNK or vehicle (ethanol) application alone. There were no statistically significant differences in the responses observed in each of these PBS-treated control groups.
